Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 5/20 | 0.45 |
| ▸ | F10 | P00742 | 5/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 2/20 | 0.43 |
| ▸ | ARAF | P10398 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865273 | 0.88 | GPR119 (0.49) | RORCBRD4 | |
| SCHEMBL5864995 | 0.88 | RORC (0.49) | RORCUTS2RBRD4KDM4ELMNA | |
| SCHEMBL5865064 | 0.79 | RORC (0.48) | RORCUTS2RKDM4ELMNAFPR2 | |
| SCHEMBL21465789 | 0.79 | BRAF (0.57) | RORCBRAFKDRF2F10 | |
| SCHEMBL5864927 | 0.79 | RORC (0.50) | RORCKDM4ELMNAMAPTNPSR1 | |
| SCHEMBL5864987 | 0.79 | SMN1; SMN2 (0.49) | RORCLMNAFPR2PROKR1 | |
| SCHEMBL5864923 | 0.78 | RORC (0.45) | RORCKDM4ELMNA | |
| SCHEMBL5865205 | 0.78 | RORC (0.47) | RORCF2F10KDM4ELMNA | |
| SCHEMBL5864758 | 0.78 | RORC (0.47) | RORC | |
| SCHEMBL5864754 | 0.77 | KDM4E (0.49) | RORCKDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | RORC 4836/4885BRAF 228/4885KDR 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.